Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest Graft-versus-host disease Stories

2011-07-28 07:47:00

PRINCETON, N.J., July 28, 2011 /PRNewswire/ -- Soligenix, Inc. (Soligenix or the Company) (OTC BB: SNGX), a late-stage biopharmaceutical company, announces the expansion and amendment of its North American licensing partnership with Sigma-Tau Pharmaceuticals, Inc. (Sigma-Tau) for the development and commercialization of orBec® (oral beclomethasone dipropionate or Oral BDP) into the European territory. As part of the amended agreement, Sigma-Tau has made a $5 million...

2011-07-14 15:41:56

St. Jude Children's Research Hospital investigators reported markedly improved survival of pediatric patients transplanted for high-risk leukemia regardless of donor; cite treatment advances and better donor selection Bone marrow transplant survival more than doubled in recent years for young, high-risk leukemia patients treated at St. Jude Children's Research Hospital, with patients who lacked genetically matched donors recording the most significant gains. The results are believed to be the...

2011-07-07 19:00:43

Identifying a suitable donor for leukemia and lymphoma patients who need bone marrow transplants may be far easier now that results of two clinical trials show transplant results with half-matched bone marrow or umbilical cord blood are comparable to fully matched tissue, thanks in large part to the availability of effective antirejection drugs and special post-transplant chemotherapy. The finding means that nearly all patients in need of a transplant can find donors, according to Johns...

2011-07-07 05:45:00

MELBOURNE, Australia, July 7, 2011 /PRNewswire/ -- Key points: Mesoblast's first Phase 3 trial submission cleared by United States Food and Drug Administration (FDA) Rapid clearance (within 30 days) further validation of Mesoblast's clinical, regulatory, and manufacturing capabilities Mesoblast's proprietary adult stem cells expand hematopoietic precursor cells in umbilical cord blood 40-fold, enabling rapid bone marrow reconstitution with lowered risk of life-threatening Graft Versus...

2011-06-27 06:00:00

PRINCETON, N.J., June 27, 2011 /PRNewswire/ -- Soligenix, Inc. (Soligenix or the Company) (OTC BB: SNGX), a late-stage biopharmaceutical company, announces the appointment of Jerome Zeldis, MD, PhD, Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation, and Keith Brownlie, CPA, former partner at Ernst & Young, LLP to its Board of Directors. "We are delighted to be able to attract the caliber of these two biotechnology industry veterans to...

2011-06-02 06:00:00

PRINCETON, N.J., June 2, 2011 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today that it recently appointed Joseph Warusz as its new Vice President of Administration and Controller. In this role, Mr. Warusz will oversee the Accounting, Human Resources, and Administrative functions, as well as serve as the Company's Principal Accounting Officer for SEC reporting purposes. Mr. Warusz comes to Soligenix with more...

2011-05-18 16:46:46

New technique will give patients a better chance of having a successful bone marrow or organ transplant University of Minnesota Medical School researchers have discovered a method to quickly and exponentially grow regulatory T-cells "“ also known as "suppressor cells." The new process enables replication of the cells by tens of millions in several weeks, a dramatic increase over previous duplication methods. Historically, regulatory T-cells have been difficult to replicate. The new...

2011-05-13 07:00:00

PRINCETON, N.J., May 13, 2011 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today its financial results for the first quarter of 2011. Soligenix's revenues for the first quarter of 2011 were approximately $808,000 as compared to $336,000 for the first quarter of 2010. The increased revenues were primarily a result of increases in National Institutes of Health (NIH) grant revenues as the Company increased...

2011-03-29 06:00:00

PRINCETON, N.J., March 29, 2011 /PRNewswire/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today its financial results for the year ended December 31, 2010. Soligenix's revenues for the year ended December 31, 2010 were $1,947,628 as compared to $2,816,037 for the prior year, representing a decrease of $868,409, or 31%. During 2009, Soligenix received a $1 million milestone payment from Sigma-Tau...

2011-03-25 07:00:00

HOUSTON, March 25, 2011 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced that the Company received notice of a $5.7 million company commercialization award from the Cancer Prevention and Research Institute of Texas ("CPRIT"). Bellicum was the only company recommended for funding in this second round of the commercialization award program. The award will fund personnel, manufacturing, and clinical testing of Bellicum's CaspaCIDe(TM) therapy, which promises to substantially...